The company is seeking a partner for Europe to assist in future regulatory discussions after data were deemed insufficient. An additional U.S. trial confirming prasterone's effects on bone loss is expected to be complete by year-end.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
